Menu ×


Histoplasmosis Treatment Market Segmentation by Type (Acute, and Chronic); by Diagnosis (Chest CT scan, Chest X-ray, Bronchoscopy, and Others); by Drug Type (Ketoconazole, Amphotericin B, Itraconazole, and Others); and by Route of Administration (Oral, Intravenous, and Others) – Global Demand Analysis & Opportunity Outlook 2030

  • Text Size:

Extensive insights into the Growth of Histoplasmosis Treatment Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More


  • June, 2021: Novartis AG to collaborate with Hewlett Packard Enterprise to address global health challenges. Novartis is the leading pharmaceutical company distributing drugs over the years.
  • February, 2021: Sandoz announced the acquisition of cephalosporin antibiotics business of GSK, to expand its portfolio in manufacturing antibiotics.

Global Histoplasmosis Treatment Market Highlights over 2022 – 2030

The global histoplasmosis treatment market is estimated to grow at a CAGR of ~9% over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the increasing incidences of histoplasmosis, especially amongst few specific occupational groups. Histoplasmosis is a lung infection caused by a special kind of fungus found in the beat of bats and fowls. It is very common in construction workers, poultry farmers, and people with weakened immune systems. Histoplasmosis is also common among people suffering from HIV/AIDS. The growing prevalence of immune-deficiency diseases globally, is estimated to boost the market growth. According to the statistics by the World Health Organization (WHO), an estimated 37.7 million people were HIV positive, as of 2020, and over 1.5 million people acquired AIDS in 2020 itself.

Histoplasmosis Treatment Market

The market is segmented by route of administration into oral, intravenous, and others, out of which, the intravenous segment is anticipated to hold the notable share in the global histoplasmosis treatment market over the forecast period on account of faster relief action of IV administration in chronic histoplasmosis. Based on type, the acute segment is anticipated to garner the largest share during the forecast period, owing to the high prevalence and easy transmission of the disease. Acute histoplasmosis is more common, which is estimated to boost the segment growth. CLICK TO DOWNLOAD SAMPLE REPORT

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Histoplasmosis Treatment Market Regional Synopsis

On the basis of geographical analysis, the global histoplasmosis treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Middle East and Africa region is estimated to witness noteworthy growth over the forecast period on the back of growing cases of chronic histoplasmosis backed by highest prevalence of AIDS in the region. According to a report by the WHO, 25.4 million people have AIDS in the WHO African Region, as of 2020.

The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the high prevalence of histoplasmosis across various regions of United States and Canada. According to the data by the Center of Disease Control and Prevalence (CDC), 60% to 90% of the population living in Ohio and Mississippi area were diagnosed of histoplasmosis at least once in their lifetime.

Histoplasmosis Treatment Market

The global histoplasmosis treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global histoplasmosis treatment market includes the following segments:

By Type

  • Acute
  • Chronic

By Diagnosis

  • Chest CT scan
  • Chest X-ray
  • Bronchoscopy
  • Others

By Drug Type

  • Ketoconazole
  • Amphotericin B
  • Itraconazole
  • Others

By Route of Administration

  • Oral
  • Intravenous
  • Others

Growth Drivers

  • Increasing Prevalence of Histoplasmosis
  • Increasing Health Awareness amongst People
  • Rising Cases of Immunodeficiency Diseases


  • Circulation of Generic Drugs

Top Featured Companies Dominating the Market

  • Alembic Limited
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Eli Lilly and Company
  • Hindustan Antibiotics Limited
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • Sanofi-aventis Groupe
  • Abbott Laboratories
  • Merck & Co., Inc.
  • Siemens Healthcare GmbH
  • Pfizer Inc.


Related Reports

Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved